Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib and trametinib price?
Diltiazem drug class?
Mebendazole 100mg price?
Alogliptin benzoate cost?
Brenzavvy discontinuation?

Vyvanse loss of appetite?

See the DrugPatentWatch profile for Vyvanse

Vyvanse (lisdexamfetamine dimesylate) is associated with appetite suppression as a common side effect [1]. This occurs because amphetamine-based medications like Vyvanse can affect the central nervous system, influencing appetite-regulating hormones and neurotransmitters [2].

Why does Vyvanse cause appetite loss?


Vyvanse works by increasing levels of certain neurotransmitters in the brain, including dopamine and norepinephrine. These neurotransmitters play a role in regulating mood, attention, and also appetite. The increase in these chemicals can lead to a decreased desire to eat [3].

How significant is the appetite loss with Vyvanse?


Appetite suppression is one of the most frequently reported side effects of Vyvanse. For some individuals, this can lead to unintentional weight loss. It is important for patients to discuss any significant changes in appetite or weight with their healthcare provider [4].

What can be done about Vyvanse-related appetite loss?


Healthcare providers may suggest strategies to manage appetite loss, such as eating smaller, more frequent meals or focusing on nutrient-dense foods. In some cases, adjusting the dosage or timing of the medication might be considered, although this should only be done under medical supervision [4].

When did Vyvanse patents expire?


The patent landscape for Vyvanse is complex, with various patents covering different aspects of the drug, including its composition of matter, methods of use, and formulations [5]. As of late 2023, some key patents for Vyvanse have expired or are nearing expiration, opening the door for potential generic competition [5][6]. DrugPatentWatch.com tracks these patent expirations and related developments [5].

What happens when Vyvanse patents expire?


Patent expiration generally allows for the development and marketing of generic versions of the drug. Generic Vyvanse, if approved by regulatory agencies, could offer a lower-cost alternative to the brand-name medication [6].

Are there alternatives to Vyvanse for appetite issues?


For conditions like ADHD, for which Vyvanse is prescribed, there are other stimulant and non-stimulant medications available that may have different side effect profiles. Non-stimulant options might also be considered for individuals who experience significant appetite suppression with stimulants [7].

---
Sources:

[1] Vyvanse Prescribing Information
[2] National Institute on Drug Abuse. (2020). Stimulant Addiction.
[3] Galshteyn, I., & Lerman, S. E. (2022). Amphetamines. In StatPearls.
[4] Shire. (2021). Vyvanse (lisdexamfetamine dimesylate) Medication Guide.
[5] DrugPatentWatch.com
[6] FDA. (2023). ANDA Approvals.
[7] American Academy of Child & Adolescent Psychiatry. (2020). ADHD Treatment.



Other Questions About Vyvanse :

Vyvanse ndc? Shire coupons for vyvanse? Is there a generic version of vyvanse? Vyvanse brand name price? Vyvanse generi? Vyvanse 20 mg cost? Vyvanse generic vs brand?

AI-Drug Label Prescribing Information Alignment Report

96
96%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The AI evaluation and claim determination are fully supported by the supplied Vyvanse prescribing information: the boxed warning and Sections 5.1 and 9.2 explicitly state that misuse/abuse can lead to overdose and death and that risk increases with higher doses or unapproved administration methods such as snorting or injection.

Category Scores

Warnings
100
Excellent
Warnings
100
Excellent

Accurate Statements

Misuse/abuse of CNS stimulants including VYVANSE can result in overdose and death, and this risk is increased with higher doses or unapproved administration methods such as snorting or injection.
BOXED WARNING; Section 5.1 (Abuse, Misuse, and Addiction); Section 9.2 (Abuse) each include overdose/death risk with increased risk for higher doses and unapproved methods such as snorting or injection.
The claim is directly addressed in the Boxed Warning and repeated in Sections 5.1 and 9.2.
BOXED WARNING and Sections 5.1 and 9.2 contain substantially the same statements about overdose/death risk and unapproved methods such as snorting or injection.
No contraindications/omissions detected relevant to this specific claim.
The provided label text supports the specific boxed-warning/Section 5.1/9.2 content relevant to the claim; no additional label elements are required to support the narrow claim about unapproved administration and overdose/death risk.

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
The evaluated claim concerns abuse/misuse leading to overdose/death and unapproved administration routes. The provided label explicitly supports this risk statement; no misleading or unsupported risk minimization was made.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Drug Brand Mention Assessment

Branding Score
67
Visibility
71
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

associated with appetite suppression as a common side effect

Core Claims
  • Vyvanse is associated with appetite suppression as a common side effect
  • Vyvanse works by increasing dopamine and norepinephrine, which can decrease appetite
  • Appetite suppression can lead to unintentional weight loss
  • Patients should discuss significant appetite or weight changes with a healthcare provider
  • Healthcare providers may suggest eating smaller, more frequent meals or adjusting dosage/timing under medical supervision
Differentiators
  • Describes appetite loss as a common side effect linked to appetite-regulating hormones and neurotransmitters
  • Links decreased appetite to increased dopamine and norepinephrine levels
  • Includes management strategies (meal timing/food density and possible dosage/timing adjustment under supervision)
  • Separately addresses patent expiration and potential generic competition
Pricing Perception: Not Mentioned